---
title: The Last 20%
---

[Skip to content](https://insights.patentvest.com/the-last-20#main-content)

[![](https://insights.patentvest.com/hubfs/Artboard%201.svg)](https://www.patentvest.com/)

- [Why PatentVest](https://www.patentvest.com/why-patentvest/)
- [Our Solution](https://www.patentvest.com/our-solution/)
- [About Us](https://www.patentvest.com/about-us/)
  
  Show submenu for About Us 
  
    - [About PatentVest](https://www.patentvest.com/about-us/)
    - [Our Team](https://www.patentvest.com/about-us/our-team/)
    - [Our Track Record](https://www.patentvest.com/about-us/our-track-record/)
- [Contact Us](https://www.patentvest.com/contact-us/)

Open main navigation

Close main navigation

- [Why PatentVest](https://www.patentvest.com/why-patentvest/)
- [Our Solution](https://www.patentvest.com/our-solution/)
- [About Us](https://www.patentvest.com/about-us/)
  
  Show submenu for About Us 
  
    - [About PatentVest](https://www.patentvest.com/about-us/)
    - [Our Team](https://www.patentvest.com/about-us/our-team/)
    - [Our Track Record](https://www.patentvest.com/about-us/our-track-record/)
- [Contact Us](https://www.patentvest.com/contact-us/)

## PATENTVEST PULSE REPORT

# The Triple Agonist Race

# Retatrutide, Twenty-Seven Programs, and the Hidden Patent War Behind the Next Obesity Market

### Access PatentVest’s latest strategic analysis mapping the companies, patent estates, delivery platforms, and emerging competitive dynamics shaping the next era of obesity therapeutics beyond first-generation GLP-1s.

### Request access to the full analysis.

[![](https://insights.patentvest.com/hubfs/Artboard%201.svg)](https://www.patentvest.com/)

[LinkedIn](https://www.linkedin.com/company/patentvest-inc.)